Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1–CX3CL1 interaction
Cardiovascular Research

Abstract
Monocytes are central for atherosclerotic vascular inflammation. The human non-classical, patrolling subtype, which expresses high levels of CD16 and fractalkine receptor CX3CR1, strongly associates with cardiovascular events. This is most marked in renal failure, a condition with excess atherosclerosis morbidity. The underlying mechanism is not understood. This study investigated how human CD16+ monocytes modulate endothelial cell function.
In patients with kidney failure, CD16+ monocyte counts were elevated and dynamically decreased within a year after transplantation, chiefly due to a drop in CD14+CD16+ cells. The CX3CR1 ligand CX3CL1 was similarly elevated in the circulation of humans and mice with renal impairment. CX3CL1 up-regulation was also observed close to macrophage rich human coronary artery plaques. To investigate a mechanistic basis of this association, CD16+CX3CR1HIGH monocytes were co-incubated with primary human endothelium
By demonstrating endothelial proatherosclerotic gene regulation in direct contact with CD16+ monocytes, in part via cellular CX3CR1–CX3CL1 interaction, our data delineate a mechanism how this celltype can increase cardiovascular risk.
Contributors

Eva Roy-Chowdhury
Author

Nicolas Brauns
Author

Alexandra Helmke
Author

Johannes Nordlohne
Author

Jan Hinrich Bräsen
Author

Jessica Schmitz
Author

Julia Volkmann
Author

Susanne V Fleig
Author

Kristina Kusche-Vihrog
Author

Hermann Haller
Author

Sibylle von Vietinghoff
Author
You may be interested in


